drugset / Trial / NCT00549523
A Controlled Study of the Safety and Efficacy of Lessertia Frutescens in HIV-infected South African Adults
Phase 1/2
Completed
133 enrolled
University of Missouri-Columbia
National Center for Complementary and Integrative Health (NCCIH) · collabOffice of Dietary Supplements (ODS) · collab
RandomizedParallel-groupDouble-blindSupportive care
Summary
The study is a 2-stage, double-blind, randomized, placebo-controlled study in which fifty-six HIV-positive subjects will be randomized into the first stage. Interim analysis to determine continuation to stage 2 will be performed to determine continuation after 8 subjects per arm have completed a 24-week dosing regimen. Primary objectives are to determine the safety of Lessertia frutescens when used by HIV-1 infected adults with early disease, and to document the impact of Lessertia frutescens on markers of HIV disease progression. Secondary objective is to determine the effect of Lessertia frutescens on quality of life in HIV-infected adults and length of infection.
Timeline
- Start
- 2008-04
- Primary completion
- 2012-01
- Completion
- 2012-01
Publications
- Background Johnson Q, Syce J, Nell H, Rudeen K, Folk WR. A randomized, double-blind, placebo-controlled trial of Lessertia frutescens in healthy adults. PLoS Clin Trials. 2007 Apr 27;2(4):e16. doi: 10.1371/journal.pctr.0020016.
- Wilson D, Goggin K, Williams K, Gerkovich MM, Gqaleni N, Syce J, Bartman P, Johnson Q, Folk WR. Consumption of Sutherlandia frutescens by HIV-Seropositive South African Adults: An Adaptive Double-Blind Randomized Placebo Controlled Trial. PLoS One. 2015 Jul 17;10(7):e0128522. doi: 10.1371/journal.pone.0128522. eCollection 2015.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aspirine | Unknown | 400 mg | — |
| Subject | Aspirine | Unknown | 800 mg | — |
| Subject | Aspirine | Unknown | 1200 mg | — |